US COVID-19 Testing Supply Data Reveal One Million Tests Being Shipped Per Day
By HospiMedica International staff writers Posted on 31 Jul 2020 |
Illustration
Data released by a US national COVID-19 diagnostic supply registry shows that over one million SARS-CoV-2 tests are being shipped every day.
The national registry has been created by the Advanced Medical Technology Association (AdvaMed Washington, D.C., USA) in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. The tests offered by these 13 leading diagnostic manufacturers together comprise ~95% of the COVID-19 tests on the market in the US. AdvaMed is also working closely with the White House, HHS, FDA, FEMA and other key government agencies to ensure the continued supply of diagnostics tests, as well as other vital medical equipment such as PPE and ventilators, in the fight against the COVID-19 pandemic.
According to key data of the US COVID testing supply released by AdvaMed, over100 commercial tests for COVID-19 have secured authorization by the US FDA. Across leading COVID diagnostic manufacturers, roughly 80 million molecular COVID-19 tests have been manufactured and shipped since March. Manufacturers have increased molecular test production from about 450,0001 shipments per day at the start of May to over 870,0001 shipments per day by July 18. The past week’s shipping patterns show an all-time weekly high of one million tests shipped per day.
As per public sources, daily molecular test runs continue to grow rapidly as well, increasing by ~30% to date in July vs. June’s average, reaching an all-time peak of about 775,000 tests per day by mid-July. High-quality serology testing, authorized by the FDA, is now available at scale with industry capacity to manufacture 100 million tests per month.
Related Links:
Advanced Medical Technology Association (AdvaMed)
The national registry has been created by the Advanced Medical Technology Association (AdvaMed Washington, D.C., USA) in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. The tests offered by these 13 leading diagnostic manufacturers together comprise ~95% of the COVID-19 tests on the market in the US. AdvaMed is also working closely with the White House, HHS, FDA, FEMA and other key government agencies to ensure the continued supply of diagnostics tests, as well as other vital medical equipment such as PPE and ventilators, in the fight against the COVID-19 pandemic.
According to key data of the US COVID testing supply released by AdvaMed, over100 commercial tests for COVID-19 have secured authorization by the US FDA. Across leading COVID diagnostic manufacturers, roughly 80 million molecular COVID-19 tests have been manufactured and shipped since March. Manufacturers have increased molecular test production from about 450,0001 shipments per day at the start of May to over 870,0001 shipments per day by July 18. The past week’s shipping patterns show an all-time weekly high of one million tests shipped per day.
As per public sources, daily molecular test runs continue to grow rapidly as well, increasing by ~30% to date in July vs. June’s average, reaching an all-time peak of about 775,000 tests per day by mid-July. High-quality serology testing, authorized by the FDA, is now available at scale with industry capacity to manufacture 100 million tests per month.
Related Links:
Advanced Medical Technology Association (AdvaMed)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans